Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of HLX22 plus trastuzumab deruxtecan in HER2-low, hormone receptor-positive advanced or metastatic breast cancer after prior standard therapy
CTR20250296Phase 2Active
- Sponsor
- HyBioPharma
- Start
- Apr 2025
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of hlx22 and trastuzumab deruxtecan in breast cancer, sponsored by HyBioPharma. Primary endpoints: Objective response rate and Progression-free survival. Started Apr 2025; status: active.
02
Drugs
hlx22trastuzumab deruxtecan
03
Conditions
breast cancer
Beyond the preview
Go deeper on CTR20250296.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20250296.